{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:56:58Z","timestamp":1794369418755,"version":"4.9.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["Study 202018 [NCT04134728] was funded by GSK."],"award-info":[{"award-number":["Study 202018 [NCT04134728] was funded by GSK."]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1136\/ard-2023-224449","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:20:15Z","timestamp":1694438415000},"page":"1527-1537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct04134728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04134728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04134728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04333147","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04134728","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Bracher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Saurigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorrie A","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy M","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224449_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10067-017-3846-8","article-title":"Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2023-224449_bib2","doi-asserted-by":"crossref","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","article-title":"The therapeutic landscape of rheumatoid arthritis: current state and future directions","volume":"12","author":"Shams","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1136\/ard-2023-224449_bib3","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1093\/rheumatology\/keac190","article-title":"Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis","volume":"61","author":"Zhao","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224449_bib4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib5","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/rheumatology\/kev194","article-title":"Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT","volume":"54","author":"Gerhold","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224449_bib6","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, Il6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot\u2019 collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib8","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/acr.24369","article-title":"Systematic literature review of residual symptoms and an unmet need in patients with rheumatoid arthritis","volume":"73","author":"Michaud","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224449_bib9","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/acr.24264","article-title":"Pain over two years after start of biologic versus conventional combination treatment in early rheumatoid arthritis: results from a Swedish randomized controlled trial","volume":"73","author":"Olofsson","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224449_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12891-016-1192-7","article-title":"Factors predicting pain and early discontinuation of tumour necrosis factor-alpha-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register","volume":"17","author":"McWilliams","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1136\/ard-2023-224449_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224449_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3389\/fimmu.2019.01265","article-title":"Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update","volume":"10","author":"Lotfi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224449_bib13","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/annrheumdis-2014-205234","article-title":"Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis","volume":"74","author":"Greven","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/ar318","article-title":"Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease","volume":"3","author":"Cook","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1136\/ard-2023-224449_bib15","doi-asserted-by":"crossref","first-page":"e20190945","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2023-224449_bib16","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1523\/JNEUROSCI.2268-19.2020","article-title":"Granulocyte-macrophage colony stimulating factor as an indirect mediator of nociceptor activation and pain","volume":"40","author":"Tewari","year":"2020","journal-title":"J Neurosci"},{"key":"10.1136\/ard-2023-224449_bib17","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1172\/JCI87828","article-title":"Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation","volume":"126","author":"Achuthan","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2023-224449_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2016-210624","article-title":"A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224449_bib20","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.4049\/jimmunol.161.7.3639","article-title":"Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice","volume":"161","author":"Campbell","year":"1998","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-224449_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/19420862.2015.1099774","article-title":"Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody","volume":"8","author":"Eylenstein","year":"2016","journal-title":"MAbs"},{"key":"10.1136\/ard-2023-224449_bib22","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2665-9913(20)30229-0","article-title":"Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2B, dose-ranging study","volume":"2","author":"Buckley","year":"2020","journal-title":"Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224449_bib23","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224449_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224449_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224449_bib26","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224449_bib27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224449_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224449_bib29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ejp.1651","article-title":"The burden of pain in rheumatoid arthritis: impact of disease activity and psychological factors","volume":"24","author":"Vergne-Salle","year":"2020","journal-title":"Eur J Pain"},{"key":"10.1136\/ard-2023-224449_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"Pope","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224449_bib32","unstructured":"Gupta A, Zecchin C, Watts S, et al. Model informed selection of phase III dosing regimens not fully tested in phase II: Anti-GM-CSF mAb, GSK3196165 (otilimab) in moderate to severe rheumatoid arthritis. American Conference on Pharmacometrics; Orlando, FL, 2019."},{"key":"10.1136\/ard-2023-224449_bib33","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2665-9913(20)30224-1","article-title":"MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2A randomised mechanistic study","volume":"2","author":"Genovese","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224449_bib34","doi-asserted-by":"crossref","first-page":"rkac002","DOI":"10.1093\/rap\/rkac002","article-title":"Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to Janus kinase inhibitors or tocilizumab in regular care in Germany","volume":"6","author":"Tony","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"10.1136\/ard-2023-224449_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1136\/ard-2023-224449_bib36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/berh.2000.0123","article-title":"Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis","volume":"15","author":"Tak","year":"2001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2023-224449_bib38","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1136\/ard-2023-224449_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-019-0066-3","article-title":"Pulmonary alveolar proteinosis","volume":"5","author":"Trapnell","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1136\/ard-2023-224449_bib40","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/ncomms8375","article-title":"Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis","volume":"6","author":"Piccoli","year":"2015","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-224449_bib41","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/s41598-018-26984-3","article-title":"GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection","volume":"8","author":"Benmerzoug","year":"2018","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-224449_bib42","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(20)30352-0","article-title":"The efficacy and safety of targeting GM-CSF in arthritis","volume":"2","author":"Bykerk","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224449_bib43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/1756-185X.13395","article-title":"Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis","volume":"22","author":"Guo","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2023-224449_bib44","doi-asserted-by":"crossref","first-page":"2101870","DOI":"10.1183\/13993003.01870-2021","article-title":"A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)","volume":"61","author":"Patel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1136\/ard-2023-224449_bib45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40744-019-00179-2","article-title":"Physical and emotional burden of rheumatoid arthritis: data from RA Matters, a web-based survey of patients and healthcare professionals","volume":"6","author":"Alten","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2023-224449_bib46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5665\/sleep.1742","article-title":"Sleep loss exacerbates fatigue, depression, and pain in rheumatoid arthritis","volume":"35","author":"Irwin","year":"2012","journal-title":"Sleep"},{"key":"10.1136\/ard-2023-224449_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41687-021-00318-w","article-title":"Qualitative and psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis","volume":"5","author":"Becker","year":"2021","journal-title":"J Patient Rep Outcomes"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:35:14Z","timestamp":1739504114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0003496724083626"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224449","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/ard-2023-224449.supp1","asserted-by":"subject"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224904","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}